Opthea Ltd (CKDXF)

Ceryvyn Therapeutics Ltd is a clinical-stage biopharmaceutical company developing therapies for the rare lung disease lymphangioleiomyomatosis (LAM). Its lead program, CYV-101, is a fusion protein designed to neutralize VEGF-C and VEGF-D, key signaling proteins involved in the disease. The company was formerly known as Opthea Limited.

Sector: Biological Products, (No Diagnostic Substances)

Industry: Biotechnology